brain cancer

[Biochemical Journal] Both glioblastoma stem cells, grown in classical 2D culture and in 3D-tumor organoids, formed functional tunneling nanotubes which allowed mitochondria transfer.

[Brain] Researchers recapitulated the immunosuppression observed in glioblastoma patients in the C57BL/6 mouse and investigated the aetiology of low CD4 T-cell counts.

[Trends in Neuroscience] Scientists focus on recent findings on extracellular vesicle-mediated bilateral crosstalk, between glioblastoma cells and astrocytes, highlighting the protumor and antitumor roles of astrocytes in glioblastoma development.

[Faseb Journal] Researchers developed a simple 3D in vitro model to better replicate brain metastasis using human cancer cells and human embryonic stem cell‐derived cerebral organoids.

[NOXXON Pharma N.V.] NOXXON Pharma N.V. announced the collaboration with three additional clinical sites to increase recruitment capacity for the Phase I/II brain cancer study of NOX-A12 plus radiotherapy, as a measure to ensure the timely completion of the study under the current challenging conditions posed by the COVID-19 pandemic.

[Noxxon Pharma N.V.] Biotechnology company NOXXON Pharma N.V. announced that all three patients of the second dose cohort have been enrolled into the brain cancer clinical trial testing CXCL12 inhibitor, NOX-A12, and have already received the planned initial treatment. The Phase I/II clinical study investigates three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external beam radiotherapy in newly diagnosed brain cancer patients.